Drug Profile
EV 048
Alternative Names: rEV 048Latest Information Update: 04 Jan 2007
Price :
$50
*
At a glance
- Originator Evolutec
- Class
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Shock
Most Recent Events
- 15 Jan 2002 rEV 048 is available for licensing (http://www.evolutec.co.uk)
- 15 Jan 2002 Preclinical development for Shock in United Kingdom (Unknown route)